Back

Effects on re-endothelialisation with Bydureon treatment add on to insulin versus insulin alone, both in combination with metformin in type 2 diabetic subjects: Rebuild study

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Drug-related risk management in chronic coronary syndromes Revascularisation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Irene Santos-Pardo

Germans Trias and Pujol Hospital, Badalona (Spain)

6 More presentations in this session

Presentation thumbnail
Risk of myocardial infarction following capecitabine treatment in patients with gastrointestinal cancer - a nationwide registry-based study
Doctor J. Shanmuganathan (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Non-clinical evaluation of YN001-a promising drug for atherosclerotic therapy by targeted delivery system
Doctor Q. Ma (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Combination of nicorandil and beta-adrenergic receptor blockers in patients with coronary heart disease: a real-world observational study
Professor N. Zhou (Wuhan, CN)
Abstract Slides Video
Presentation thumbnail
Cardioprotective potential of exosomes derived from blood outgrowth endothelial cells in ischemic cardiomyopathy
Doctor M. Wu (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
PSRC1 rs599839 G allele may promote protection from coronary artery disease in a Madeira Island population
Mr F. Sousa (Funchal, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Drug-related risk management in chronic coronary syndromes

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
GLP1 receptor agonists and CAD regression in diabetic patients after ACS
thumbnail
Congress Presentation
The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease
thumbnail
Congress Session
Molecular actions of GLP-1 agonists and incretins

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources